NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Belumosudil for treating chronic graft versus host disease after 2 or more therapies ID4021

Provisional Stakeholder List

Consultees	**Commentators (no right to submit or appeal)**
Company • Sanofi (belumosudil) Patient/carer groups • African-Caribbean Leukaemia Trust • Anthony Nolan • Aplastic Anaemia Trust • Blood Cancer UK • Cianna's Smile • CML Support Group • DKMS • Immunodeficiency UK • Leukaemia Cancer Society • Leukaemia Care • Lymphoma Action • Macmillian Cancer Support • MDS UK Patient Support Group • MPS Society • Myeloma UK • Sickle Cell Society • Sickle Cell and Young Stroke Survivors • SickleKan • South Asian Health Foundation • Specialised Healthcare Alliance • The Essenelle Foundation • UK Thalassaemia Society Healthcare professional groups • British Blood Transfusion Society • British Committee for Standards in Haematology • British Geriatrics Society • British Society for Genetic Medicine • British Society for Haematology	General • All Wales Inherited Metabolic Disease Service Cardiff • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • National Services Division • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee Possible comparator companies • Accord Healthcare (methotrexate, mycophenolate mofetil) • ADVANZ Pharma (methotrexate) • Cipla EU (methotrexate) • Hospira (methotrexate) • Medac (methotrexate) • Morningside Healthcare (methotrexate) • Nordic Pharma (methotrexate) • Novartis Pharmaceuticals UK (mycophenolate mofetil)

Consultees	**Commentators (no right to submit or appeal)**
• British Society for Immunology • British Society of Blood and Marrow Transplantation and Cellular Therapy • British Transplantation Society • Cancer Research UK • Neonatal and Paediatric Pharmacists Group • NHS Blood and Transplant • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics and Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Forum on Haemoglobin Disorders • UK Primary Immunodeficiency Network <u>Others</u> • Department of Health and Social Care • Christie Haematology and Transplant Unit (Manchester) • King's College London – Haemato-oncology department • NHS England • St James University Hospital Bone Marrow Transplant Department (Leeds Teaching Hospitals Trust) • University College London Hospitals HSCT Service	• Orion Pharma UK (methotrexate) • Pfizer (methotrexate) • Roche Products (mycophenolate mofetil) • Rosemont Pharmaceutical (methotrexate) • Sandoz Limited (methotrexate, mycophenolate mofetil) • Teva Pharma (mycophenolate mofetil) • Therakind (methotrexate) • Tillomed Laboratories (mycophenolate mofetil) <u>Relevant research groups</u> • Cochrane Haematological Malignancies Group • Cochrane UK • Genomics England • Leukaemia Busters • MRC Clinical Trials Unit • National Institute for Health Research • Oxford Biomedical Research Centre <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

[1] Non-company consultees are invited to submit statements relevant to the group they are representing.

